PT3463328T - Seladelpar para o tratamento de colangite biliar primária - Google Patents

Seladelpar para o tratamento de colangite biliar primária

Info

Publication number
PT3463328T
PT3463328T PT177229432T PT17722943T PT3463328T PT 3463328 T PT3463328 T PT 3463328T PT 177229432 T PT177229432 T PT 177229432T PT 17722943 T PT17722943 T PT 17722943T PT 3463328 T PT3463328 T PT 3463328T
Authority
PT
Portugal
Prior art keywords
seladelpar
treatment
primary biliary
biliary cholangitis
cholangitis
Prior art date
Application number
PT177229432T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Cymabay Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cymabay Therapeutics Inc filed Critical Cymabay Therapeutics Inc
Publication of PT3463328T publication Critical patent/PT3463328T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Farming Of Fish And Shellfish (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT177229432T 2016-05-31 2017-04-26 Seladelpar para o tratamento de colangite biliar primária PT3463328T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662343688P 2016-05-31 2016-05-31

Publications (1)

Publication Number Publication Date
PT3463328T true PT3463328T (pt) 2022-07-07

Family

ID=58699276

Family Applications (1)

Application Number Title Priority Date Filing Date
PT177229432T PT3463328T (pt) 2016-05-31 2017-04-26 Seladelpar para o tratamento de colangite biliar primária

Country Status (27)

Country Link
US (5) US10272058B2 (enExample)
EP (1) EP3463328B1 (enExample)
JP (1) JP7079735B2 (enExample)
KR (1) KR102408288B1 (enExample)
CN (2) CN121466055A (enExample)
AU (1) AU2017274293B2 (enExample)
BR (1) BR112018074147A2 (enExample)
CA (1) CA3024155C (enExample)
CY (1) CY1125465T1 (enExample)
DK (1) DK3463328T3 (enExample)
ES (1) ES2921230T3 (enExample)
HR (1) HRP20220903T1 (enExample)
HU (1) HUE059838T2 (enExample)
IL (1) IL263372B2 (enExample)
LT (1) LT3463328T (enExample)
MX (1) MX390417B (enExample)
NZ (1) NZ748721A (enExample)
PL (1) PL3463328T3 (enExample)
PT (1) PT3463328T (enExample)
RS (1) RS63345B1 (enExample)
RU (1) RU2765460C2 (enExample)
SG (1) SG11201810123SA (enExample)
SI (1) SI3463328T1 (enExample)
SM (1) SMT202200471T1 (enExample)
UA (1) UA122719C2 (enExample)
WO (1) WO2017209865A1 (enExample)
ZA (1) ZA201808360B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
HRP20181914T1 (hr) 2014-03-20 2019-01-11 Cymabay Therapeutics, Inc. Liječenje intrahepatičnih kolestatskih bolesti
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
EP3880185A1 (en) * 2018-11-16 2021-09-22 CymaBay Therapeutics, Inc. Combination treatment of nafld and nash
AU2022214948B2 (en) * 2021-02-01 2023-07-13 Cymabay Therapeutics, Inc. Treatment of cholangiopathies with seladelpar
WO2024180642A1 (ja) 2023-02-28 2024-09-06 株式会社日立ハイテク プラズマ処理装置およびプラズマ処理装置の試料台の製造方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7101993B1 (en) 1990-01-11 2006-09-05 Isis Pharmaceuticals, Inc. Oligonucleotides containing 2′-O-modified purines
US7015315B1 (en) 1991-12-24 2006-03-21 Isis Pharmaceuticals, Inc. Gapped oligonucleotides
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US6166197A (en) 1995-03-06 2000-12-26 Isis Pharmaceuticals, Inc. Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
EP0813539B1 (en) 1995-03-06 2006-05-24 Isis Pharmaceuticals, Inc. Improved process for the synthesis of 2'-o-substituted pyrimidines and oligomeric compounds therefrom
KR19990082476A (ko) 1996-02-14 1999-11-25 하우스 한스 루돌프, 긴터 베아트리체 당-변형되어 갭이 형성된 올리고뉴클레오티드
US5883109A (en) 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
US6066653A (en) 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US7511131B2 (en) 2002-11-13 2009-03-31 Genzyme Corporation Antisense modulation of apolipoprotein B expression
US7981915B2 (en) 2003-04-30 2011-07-19 Beth Israel Deaconess Medical Center Methods for modulating PPAR biological activity for the treatment of diseases caused by mutations in the CFTR gene
EP2100877B1 (en) 2003-09-19 2012-01-25 Janssen Pharmaceutica N.V. 4-((Phenoxyalkyl)thio)-phenoxyacetic acids and analogs
NZ549721A (en) 2004-03-05 2010-08-27 Univ Pennsylvania Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
BRPI0920170A2 (pt) 2008-10-17 2016-06-21 Metabolex Inc métodos para diminuir a quantidade de partículas ldl pequenas e densas e de níveis de triglicerídeos e ldl no sangue em um humano, e para identificar um indivíduo candidato para tratamento com um composto ou um sal, prodroga ou isômero do mesmo, composto ou um sal, prodroga ou isômero do mesmo, e método.
NZ720946A (en) * 2009-04-29 2017-09-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
US9061012B2 (en) 2010-03-30 2015-06-23 Novartis Ag Uses of DGAT1 inhibitors
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
WO2015077154A1 (en) 2013-11-20 2015-05-28 Cymabay Therapeutics, Inc. Treatment of homozygous familial hypercholesterolemia
US20160279085A1 (en) 2013-11-20 2016-09-29 Cymabay Therapeutics, Inc. Treatment of Severe Hyperlipidemia
HRP20181914T1 (hr) 2014-03-20 2019-01-11 Cymabay Therapeutics, Inc. Liječenje intrahepatičnih kolestatskih bolesti
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
SG11201608077PA (en) 2014-04-11 2016-10-28 Cymabay Therapeutics Inc Treatment of nafld and nash
MX2016017081A (es) 2014-06-26 2017-05-01 Cymabay Therapeutics Inc Tratamiento de hipertrigliceridemia grave.
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
SI3973959T1 (sl) 2017-09-26 2025-03-31 Cymabay Therapeutics, Inc. Zdravljenje holestatskega pruritusa s seladelparjem
EP3880185A1 (en) 2018-11-16 2021-09-22 CymaBay Therapeutics, Inc. Combination treatment of nafld and nash
EP3880187A1 (en) 2018-11-16 2021-09-22 CymaBay Therapeutics, Inc. Treatment of obesity and its complications

Also Published As

Publication number Publication date
IL263372A (en) 2018-12-31
EP3463328A1 (en) 2019-04-10
US20210220305A1 (en) 2021-07-22
AU2017274293B2 (en) 2022-03-31
ZA201808360B (en) 2020-02-26
UA122719C2 (uk) 2020-12-28
JP2019518022A (ja) 2019-06-27
WO2017209865A1 (en) 2017-12-07
KR20190015363A (ko) 2019-02-13
SMT202200471T1 (it) 2023-01-13
US10272058B2 (en) 2019-04-30
US20200061006A1 (en) 2020-02-27
HUE059838T2 (hu) 2023-01-28
US10813895B2 (en) 2020-10-27
HRP20220903T1 (hr) 2022-10-14
IL263372B2 (en) 2023-06-01
US20210000774A1 (en) 2021-01-07
CA3024155A1 (en) 2017-12-07
ES2921230T3 (es) 2022-08-22
US11596614B2 (en) 2023-03-07
CN109195594A (zh) 2019-01-11
EP3463328B1 (en) 2022-06-15
BR112018074147A2 (pt) 2019-03-06
RU2018146504A3 (enExample) 2020-07-27
MX2018014915A (es) 2019-04-24
CN121466055A (zh) 2026-02-06
RU2765460C2 (ru) 2022-01-31
LT3463328T (lt) 2022-08-10
US20190255004A1 (en) 2019-08-22
MX390417B (es) 2025-03-20
KR102408288B1 (ko) 2022-06-10
CA3024155C (en) 2023-10-10
SI3463328T1 (sl) 2022-08-31
JP7079735B2 (ja) 2022-06-02
RS63345B1 (sr) 2022-07-29
US11000494B2 (en) 2021-05-11
PL3463328T3 (pl) 2022-10-03
DK3463328T3 (da) 2022-07-04
AU2017274293A1 (en) 2018-12-13
SG11201810123SA (en) 2018-12-28
NZ748721A (en) 2022-04-29
US10478411B2 (en) 2019-11-19
RU2018146504A (ru) 2020-07-09
US20170340589A1 (en) 2017-11-30
CY1125465T1 (el) 2025-05-09

Similar Documents

Publication Publication Date Title
CY2025027I2 (el) Ελαφιμπρανορη για χρηση στην αντιμετωπιση πρωτοπαθους χολικης χολαγγειτιδας
HUS2100037I1 (hu) Vegyületek gerinc eredetû izomsorvadás kezelésére
DK3728271T3 (da) Makrocykliske forbindelser til behandling af sygdomme
DK3501542T3 (da) Esketamin til behandling af depression
DK3212233T3 (da) Kombinationsterapi til behandling af sygdom
DK3504187T3 (da) Anvendelse af pridopidin til behandling af funktionel tilbagegang
DK3362066T3 (da) Kombinationsterapi til behandling af maligniteter
DK3125875T3 (da) Inhalerbar rapamycinformulering til behandling af aldersrelaterede tilstande
HUE055263T2 (hu) 11-Szubsztituált 24-hidroxiszterolok NMDA-hoz kapcsolódó állapotok kezelésére
DK3185957T3 (da) Patisiran til anvendelse ved behandlingen af transthyretin-medieret amyloidosis
DK3503890T3 (da) Anvendelse af pridopidin til behandling af dystonier
ZA201903649B (en) Treatment for primary biliary cholangitis
BR112016022976A2 (pt) Métodos para o tratamento de hcv
LT3463328T (lt) Seladelparas pirminiam tulžies cholangitui gydyti
DK3430143T3 (da) Inhibitorer af SRSF1 til behandlingen af neurodegenerative sygdomme
DK3331610T3 (da) Midler til anvendelse til behandling af gliom
DK3286317T3 (da) Dynamin 2-inhibitor til behandlingen af duchennes muskeldystrofi
DK3506901T3 (da) Anvendelse af kynurensyre til behandling af muskelatrofi
CY2024037I1 (el) Χρηση delgocitinib για την θεραπεια χρονιουεκζεματος χεριων
EP3493821A4 (en) METHOD OF TREATING THE RESPIRATORY TRACT
DK3478713T3 (da) Sammensætninger til behandling af amyloidose
DK3448340T3 (da) Applikationshjælpemiddel til behandling af sår
DK3250218T3 (da) Naktidpeptid til behandling af fedme
DK3548006T3 (da) Sammensætning til behandling af tarmforandringer
DK3710012T3 (da) Fremgangsmåder til testosteronbehandling